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The discovery, in 2006, that loss-of-function mutations
in the filaggrin (FLG) gene are the cause of ichthyosis
vulgaris—the most common disorder of keratiniza-
tion—and also a strong genetic risk factor for atopic
eczema, marked a significant breakthrough in the
understanding of eczema pathogenesis. Subsequent
investigations of the role of FLG-null mutations have
identified a series of significant associations with
atopic disease phenotypes, including atopic asthma,
allergic rhinitis, and peanut allergy. However, many
questions remain to be answered in relation to the
precise mechanisms by which deficiency of an
intracellular protein expressed primarily in the differ-
entiating epidermis may contribute to the develop-
ment of cutaneous and systemic pathology. This
review aims to highlight the key milestones in
filaggrin research over the past 25 years, to discuss
the mechanistic, clinical, and therapeutic implications,
and to consider possible future directions for ongoing
investigation.
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A BRIEF HISTORY OF FILAGGRIN, FROM ICHTHYOSIS
VULGARIS TO MODERN MOLECULAR GENETICS
Ichthyosis vulgaris (OMIM (Online Mendelian Inheritance in
Man) #146700) is the most common inherited disorder of
keratinization, with an estimated prevalence of between 1 in
80 and 1 in 250 English schoolchildren (Wells and Kerr,
1966; Brown et al., 2008a). It is an autosomal semidominant
condition with incomplete penetrance and variable expres-
sivity, such that disease severity can vary considerably even
within affected families (Smith et al., 2006). The ichthyosis is
often asymptomatic, although patients may complain of dry,
rough skin and cosmetic embarrassment. The disease is
characterized by fine scaling, which is most apparent on the
lower abdomen, extensor aspects of arms and lower legs,
with sparing of the flexures (Judge et al., 2004). The
semiadherent scales are white or gray and the ichthyosis
varies with environmental conditions, being more severe in
cold, dry weather and sometimes resolving completely in a
hot, humid environment (DiGiovanni, 2003). The palms and
soles are not scaly, but show hyperlinearity, particularly on
the thenar eminence (Judge et al., 2004; Brown et al., 2009).
Keratosis pilaris is another feature of ichthyosis vulgaris
(Mevorah et al., 1985; DiGiovanni, 2003), but as keratosis
pilaris is also very common in the normal population it is not
a discriminatory clinical sign (Brown et al., 2008a).
Historically, several convergent lines of reasoning led to a
study of the filaggrin (FLG) gene as a cause for ichthyosis
vulgaris. Skin biopsies from patients with ichthyosis vulgaris
showed a reduction or absence of keratohyalin granules (the
main component of which is profilaggrin) by light micro-
scopy (Sybert et al., 1985; Manabe et al., 1991; Smith et al.,
2006), and by electron microscopy the granules were noted
to be abnormally shaped or completely absent (Sybert et al.,
1985; Smith et al., 2006). Immunostaining of ichthyosis
vulgaris skin biopsies showed a reduction in filaggrin protein
expression (Sybert et al., 1985; Fleckman et al., 1987), and a
reduction in profilaggrin mRNA within keratinocytes was also
reported (Manabe et al., 1991; Nirunsuksiri et al., 1995,
1998). The recessive mutant flaky tail mouse, an animal
model of ichthyosis vulgaris, demonstrated genetic linkage to
the mouse epidermal differentiation complex (Smith et al.,
2006) and it expressed abnormal profilaggrin that is not
proteolytically processed to filaggrin (Presland et al., 2000).
More recently, the phenotype of an absence of granules
within the cells of the granular layer was mapped to the
epidermal differentiation complex (Mischke et al., 1996) on
chromosome 1q21 (Compton et al., 2002).
These observations date from the mid 1980s (Figure 1),
and the profilaggrin gene was partially sequenced in 1992
(Presland et al., 1992). However, the identification of loss-of-
function mutations was delayed until 2006 because FLG is a
very large and repetitive gene (Figure 2), making sequencing
using conventional PCR technically difficult. The formidable
challenge of fully sequencing FLG exon 3 was eventually
conquered by the use of long-range PCR to amplify the whole
of exon 3, combined with short specific PCRs to amplify
multiple overlapping fragments, which could then be used to
reconstruct the repetitive sequence as a jigsaw (Figure 2;
Smith et al., 2006). The initial two loss-of-function mutations
(R501X and 2282del4) were thus identified in the first repeat
of FLG exon 3 (Smith et al., 2006).
The large and repetitive structure of the FLG gene remains
a significant challenge for routine PCR-based sequencing.
However, detailed knowledge of selected single-nucleotide
polymorphisms (SNPs), which are unique to each repeat in
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the extensively studied white European DNA collections, has
facilitated the development of repeat-selective PCR primers
for sequencing and genotyping assays (Sandilands et al.,
2007). The use of next-generation sequencing techniques for
FLG genotyping is anticipated, but careful application will be
required as it will be difficult to accurately align relatively
short sequence reads (e.g., 50–100 base pairs) across the
highly repetitive third exon, particularly in ethnic populations
for which the FLG sequence is not yet well annotated.
The presence of intragenic copy number variation (CNV)
in FLG adds a further level of complexity to the sequence
analysis. Using Southern blot analysis, three common-size
alleles encoding 10, 11, or 12 filaggrin repeats were correctly
inferred (Gan et al., 1990). These were subsequently
confirmed by sequencing and shown to be due to duplication
of filaggrin repeat 8, or duplication of both repeat 8 and
repeat 10 (Sandilands et al., 2007). Thus, null mutations
aside, the number of filaggrin units varies from 20 to 24 in the
human population. Very recently, methods have been
developed to allow the genotyping of filaggrin CNV across
large populations (Brown et al., 2011b). The CNV allele
frequencies in the Irish population were found to be 33.9%
(10 repeats), 51.5% (11 repeats), and 14.6% (12 repeats). The
shortest genotype (10,10), carried by 11.5% of Irish people,
was found to infer an eczema risk of 1.67, independent of the
loss-of-function mutations. Interestingly, when null mutations
are excluded, each additional filaggrin repeat gained
decreases the odds ratio for atopic eczema by 0.88 (Brown
et al., 2011b). Thus, filaggrin CNV makes a significant, dose-
dependent contribution to eczema risk, and even a modest
10–20% increase in epidermal filaggrin expression is
predicted to be therapeutic for eczema or protective against
developing eczema.
It may be pertinent to ask why the strong association of
FLG with atopic eczema was not detected by earlier genome-
wide association studies? There are a number of possible
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Figure 1. Historical perspective on filaggrin research. Inset shows immunohistochemical staining of human epidermis, with filaggrin in green,
basal-specific keratin 5 in red, and nuclei stained blue. FLG, filaggrin.
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Figure 2. Diagrammatic representation of filaggrin (FLG) gene structure and sequencing strategy. FLG is a large gene located on chromosome 1q21,
within the epidermal differentiation complex, a dense cluster of genes involved with keratinocyte terminal differentiation. The gene product is profilaggrin,
an insoluble polyprotein that is proteolyzed to release functional filaggrin monomers. Full sequencing of the FLG gene is time consuming and requiresX10 PCR
reactions and 430 sequencing reactions. bp, base pairs; UTR, untranslated region. Adapted from Smith et al. (2006) and Sandilands et al. (2007, 2009).
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explanations for this. One early genome-wide genetic study
using microsatellite markers did show linkage to the 1q21
locus (Cookson et al., 2001). Factors such as the type of
markers used and the study design based on allele transmis-
sion (rather than the current more powerful case–control
design using high-density SNPs) led to the importance of this
locus being underrecognized. Furthermore, the very strong
association of FLG with atopic eczema that we now
recognize results from the combined null genotype reflecting
the effect of two or more null mutations, a mechanism that
genome-wide association using tagging SNPs is not designed
to detect. The most recently published genome-wide study
was designed with SNPs tagging the FLG locus and a strong
signal was observed (Esparza-Gordillo et al., 2009). It
remains to be determined whether this signal is entirely
attributable to FLG loss-of-function mutations or whether
other genetic factors nearby in the epidermal differentiation
complex of genes also contribute to eczema risk. CNV within
the FLG gene contributes to eczema risk, independent of the
null mutations (Brown et al., 2011b). This has yet to be
factored into interpretation of the genome-wide association
data for the 1q21 locus.
PROFILAGGRIN AND FILAGGRIN ARE
MULTIFUNCTIONAL PROTEINS IN THE MAINTENANCE
OF AN OPTIMAL SKIN BARRIER
The large (4400 kDa), insoluble polyprotein profilaggrin is
dephosphorylated and degraded to produce monomeric
filaggrin in the stratum corneum and then further proteolyzed
to release its component amino acids. Profilaggrin, filaggrin,
and the amino acids each make different contributions to
epidermal structure and barrier function (Figure 3), but the
exact mechanisms by which profilaggrin and filaggrin, as
intracellular proteins, contribute to what appears to be a
paracellular barrier defect (Scharschmidt et al., 2009; Gruber
et al., 2011) remain to be defined.
Profilaggrin forms the major component of the keratohya-
lin granules that are visible by light microscopy within the
granular layer of the epidermis. The profilaggrin molecule
(Figure 2) is composed of an N-terminal domain, which has
calcium-binding and nuclear localization components, fol-
lowed by 10, 11, or 12 nearly identical filaggrin repeats,
which have keratin-binding properties, plus a C-terminal
domain of unknown function (Sandilands et al., 2009). Each
of these components has a different function in the
differentiating epidermis. The S100-like calcium-binding
domain (Markova et al., 1993) may have a role in the
regulation of calcium-dependent events during terminal
epidermal differentiation (Presland et al., 1992; Nirunsuksiri
et al., 1995) or, conversely, calcium may be involved in the
control of profilaggrin processing (Presland et al., 2004;
Sandilands et al., 2009). The N-terminal domain is cleaved
from profilaggrin and translocates to the nucleus where it
may have a role in the enucleation of keratinocytes in the
outer stratum corneum (Sandilands et al., 2009). The precise
function of the C-terminal domain is unclear, but it is known
to be required for the processing of profilaggrin to filaggrin.
Loss-of-function mutations within FLG exon 3 result in a
truncated profilaggrin molecule, which lacks the C terminus,
resulting in an almost complete absence of filaggrin
monomers (Sandilands et al., 2007). Each of the reported
FLG-null mutations therefore have an equivalent molecular
biological effect, as they each produce biochemically
unstable truncated profilaggrin that cannot be processed to
release functional filaggrin.
Monomeric filaggrin binds to keratins 1 and 10 and other
intermediate filament proteins within the keratinocyte cytos-
keleton to form tight bundles (Manabe et al., 1991),
facilitating the collapse and flattening of cells in the outer-
most stratum corneum to produce squames. This process of
cell flattening is still seen to occur in the absence of
processed filaggrin; however, on an ultrastructural level, it
appears that loss-of-function mutations in FLG may be
associated with disorganized keratin filaments, impaired
lamellar body loading, and abnormal architecture of the
lamellar bilayer (Gruber et al., 2011). A reduction in
corneodesmosome density and tight-junction protein expres-
sion has also been observed in the skin from ichthyosis
vulgaris patients (Gruber et al., 2011). It is unclear as to how
these observations may be attributable to filaggrin deficiency
from our current understanding of filaggrin processing, and
they may represent secondary effects. Filaggrin contributes to
the protein–lipid cornified cell envelope, which replaces the
plasma membrane of differentiating keratinocytes and is
extensively crosslinked by transglutaminases, forming a
barrier to water loss and minimizing the entry of allergens
and microorganisms (Candi et al., 2005).
Filaggrin is ultimately deiminated and degraded on the
skin surface to release its component amino acids. A mixture
of hygroscopic amino acids at an estimated concentration
of 100mM millimolar (Candi et al., 2005) is produced, the
Keratinocyte
calcium
signaling
Main
constituent of
keratohyalin
granules
Enucleation
during
cornification
Acidification Anti-
staphylococcal
effect
Photoprotection
and
immunomodulation
Aggregation
of intermediate
filaments
Inhibition of
transepidermal
water loss
Contribution to
stratum corneum
structure and
function
Stratum
corneum
hydration
Profilaggrin
Filaggrin
Amino acids
Figure 3. Profilaggrin, filaggrin, and their constituent amino acids are
multifunctional proteins contributing to the formation and function of the
skin barrier. Diagram summarizing the known and possible functions of
profilaggrin, filaggrin, and amino acids released by filaggrin proteolysis.
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so-called ‘‘natural moisturizing factor’’ (Rawlings and Hard-
ing, 2004), which contributes to epidermal hydration and
barrier function. FLG-null mutations are associated with
lower levels of hygroscopic amino acids in the stratum
corneum of human subjects, measured using Raman spectro-
scopy, and there is a concomitant increase in transepidermal
water loss (Kezic et al., 2008).
Three published studies describing murine models of
filaggrin haploinsufficiency have shown a barrier impairment
and enhanced percutaneous allergen sensitization (Man
et al., 2008; Fallon et al., 2009; Oyoshi et al., 2009). The
barrier integrity phenotype associated with FLG-null muta-
tions in human skin is currently emerging, with evidence of a
significant reduction in natural moisturizing factors in the
stratum corneum, to which filaggrin breakdown products
contribute (Kezic et al., 2008, 2011; O’Regan et al., 2010b),
as well as FLG genotype-related impairment in stratum
corneum integrity and cohesion (Angelova-Fischer et al.,
2011). However, eczema severity is itself associated with a
reduction in natural moisturizing factor concentrations, and
the debate is set to continue with regard to the relative
importance of epidermal defects and immune dysregulation
as the key initiating factors in eczema pathogenesis (Hudson,
2006; Elias and Schmuth, 2009; Vercelli, 2009; Simpson,
2010).
Filaggrin is a histidine-rich protein (Lynley and Dale,
1983) and histidine is metabolized to trans-urocanic acid
(trans-UCA); pyrrolidone-5-carboxylic acid is the other main
breakdown product of filaggrin, and together these organic
acids help maintain the pH gradient of the epidermis as
evidenced by a higher surface pH in FLG-null mutation
carriers (Jungersted et al., 2010). The ‘‘acid mantle’’ of the
stratum corneum has a well-known antimicrobial effect, and
there is evidence that filaggrin breakdown products at
physiological concentrations demonstrate an inhibitory effect
on the growth of Staphyloccus aureus (Miajlovic et al., 2010).
An acidic pH within the stratum corneum is also important
for the functional activity of enzymes involved in ceramide
metabolism (Fluhr et al., 2010). The acidic pH also modulates
the activity of the serine protease cascade (Ovaere et al.,
2009) required for coordinated epidermal differentiation and
cornified cell envelope formation. Finally, a possible role of
filaggrin breakdown products in UV photoprotection has
been suggested. The photoisomerization of trans-UCA to cis-
UCA (Elias and Choi, 2005) produces a molecule with an
action spectrum of 280–310 nm (McLoone et al., 2005),
which is within the UVB range, and there is in vitro evidence
that cis-UCA has immunomodulatory actions in human
keratinocytes and leukocytes (Gilmour et al., 1993; McLoone
et al., 2005). There is also recent in vitro evidence from an
organotypic siRNA FLG knockdown model that lack of
filaggrin leads to a reduction in UCA concentration and an
increased sensitivity to UV-induced apoptosis (Mildner et al.,
2010).
Filaggrin and filaggrin-related proteins are expressed in the
skin of mammals including monotremes, but these molecules
are not well conserved and are difficult to identify in lower
animal orders. Filaggrin biology has been most extensively
studied in mouse and canine species (Man et al., 2008; Fallon
et al., 2009; Marsella and Girolomoni, 2009; Oyoshi et al.,
2009; Chervet et al., 2010; Moniaga et al., 2010; Hoste et al.,
2011; Matsui et al., 2011). These and other experimental
models will continue to contribute to our understanding of
the functions of this remarkable molecule.
FILAGGRIN HAPLOINSUFFICIENCY PLAYS A KEY ROLE
IN PHENOTYPIC VARIATION AND COMMON
DISORDERS OF THE SKIN
Filaggrin haploinsufficiency (i.e., a lack of filaggrin protein
resulting from a heterozyous loss-of-function mutation)
contributes to several common dermatological disorders.
Ichthyosis vulgaris is a semidominant disorder in which
individuals with two FLG-null mutations have a more severe
phenotype than those with one FLG-null mutation. The
characteristic skin scaling in ichthyosis vulgaris may logically
be attributed to the known functions of FLG, but the
mechanisms by which FLG haploinsufficiency contributes
to the associated features of keratosis pilaris and palmoplan-
tar hyperlinearity are currently unknown.
Ichthyosis vulgaris is frequently associated with atopic
eczema, and hence it was a logical next step to investigate
the association of FLG-null mutations with this disease. A
significant association was initially demonstrated in 15 Irish
families and then replicated in three separate case–control
studies from Irish, Scottish, and Danish populations (Palmer
et al., 2006). The strong and highly significant association of
FLG-null mutations with atopic eczema has subsequently
been replicated in over 20 independent studies, including
case–control studies, family studies, and unselected popula-
tion cohorts. Two recent meta-analyses of these data have
estimated the odds ratio of developing atopic eczema to be
4.78 (van den Oord and Sheikh, 2009) and 3.12 (Rodriguez
et al., 2009) in association with FLG-null genotype. The
eczema subphenotype that is most strongly associated with
FLG-null mutations is that of early-onset, severe, and
persistent disease (Barker et al., 2007; Brown et al., 2008b),
and with the associated ‘‘extrinsic’’ features of raised total IgE
and allergic sensitization (Weidinger et al., 2006, 2007).
Population cohort studies include atopic eczema of mild–-
moderate severity, and this phenotype has also demonstrated
significant association with FLG-null mutations (Henderson
et al., 2008; Brown et al., 2008a; Gruber et al., 2010).
However, mild–moderate eczema shows a lower odds ratio
than moderate–severe eczema, and its association with FLG-
null mutations may be significant only in individuals carrying
two null mutations (Brown et al., 2008a). Taking into account
all the clinical signs that may be attributable to FLG
haploinsufficiency (including atopic eczema, ichthyosis,
xerosis, palmar hyperlinearity, and keratosis pilaris), FLG-
null mutations are highly penetrant (Brown et al., 2009).
In light of the very significant association of atopic eczema
with FLG-null mutations, several other subgroups of eczema
have been investigated for their link with filaggrin. There is a
well-recognized genetic susceptibility to contact dermatitis
(Kezic, 2011), but it is often difficult to distinguish the
subgroups of irritant and allergic contact dermatitis from
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atopic dermatitis; hence, these genetic studies are difficult to
interpret (Lerbaek et al., 2007; Brown and Cordell, 2008; de
Jongh et al., 2008). Studies on FLG genotype as a risk factor
for experimentally induced irritant dermatitis have given
conflicting results (Jungersted et al., 2010; Angelova-Fischer
et al., 2011), and this may be because of methodological
differences in the concentration of irritant. Studies published
to date have reported no association of FLG genotype with
allergic contact dermatitis defined by a positive patch test
result to one or more substance (Carlsen et al., 2010) or with
a subset of patients having both atopic eczema and contact
allergy (Carlsen et al., 2011b). In contrast, FLG-null genotype
has shown significant association with nickel sensitization,
but only in a subgroup of cases reporting intolerance to
costume jewellery (Novak et al., 2008) and in a subgroup of
women who had not had their ears pierced (Thyssen et al.,
2010b). The proposed explanation for this observation is that
ear piercing is a stronger risk factor than FLG genotype (Ross-
Hansen et al., 2010), emphasizing the importance of
environmental exposures in allergy development, as well as
the need for careful phenotype definition in genetic studies.
One small study has investigated FLG genotype as a risk
factor for a type 1 hypersensitivity reaction to latex (Carlsen
et al., 2011a) and found no significant association. However,
this study should be interpreted with caution as it included
only three FLG heterozygotes, and therefore may not have
had sufficient power to exclude a significant association.
Another subgroup of atopic eczema is the severe viral
infection eczema herpeticum. Case–control studies from
European and African population groups have shown that
the loss-of-function mutation R501X confers an even greater
risk of eczema herpeticum than atopic eczema (Gao et al.,
2009), suggesting a possible role for defective skin barrier in
this viral infection.
Two other common cutaneous disorders have been
investigated with respect to a hypothetical FLG association:
psoriasis, because of its co-association with the 1q21 locus in
genome-wide scans (Bowcock et al., 2001), and acne
vulgaris, because of a possible protective effect of FLG-null
mutations (Sergeant et al., 2009). However, adequately
powered studies have shown that there is no association of
FLG loss-of-function mutations with psoriasis in the UK and
Irish populations (Zhao et al., 2007) or with acne vulgaris in
the Singaporean Chinese population (Common et al., 2011).
FLG MUTATIONS CONTRIBUTE TO GENETIC RISK AT
EACH STEP OF THE ATOPIC MARCH
The ‘‘atopic march’’ (Wuthrich and Schmid-Grendelmeier,
2003; Hahn and Bacharier, 2005; Spergel, 2010) describes
the tendency for atopic eczema to precede the development
of food allergies, asthma, and allergic rhinitis in a temporal
sequence. FLG-null mutations have been reported as a risk
factor for each step in this march: atopic eczema (Palmer
et al., 2006); allergic sensitization (van den Oord and Sheikh,
2009); the subgroup of asthma in association with eczema
(Marenholz et al., 2006; Henderson et al., 2008; Brown et al.,
2008a; Weidinger et al., 2008b); allergic rhinitis (Weidinger
et al., 2008b; Schuttelaar et al., 2009); and, most recently,
peanut allergy (Brown et al., 2011a). Thus, FLG-null alleles
are a significant risk factor for all aspects of atopy, but with
differing odds ratios for each specific phenotype. Overall,
these studies underscore the role of skin barrier dysfunction
as a key driver of allergic disease.
FLG LOSS-OF-FUNCTION MUTATIONS SHOW
POPULATION SPECIFICITY
Since the discovery of the first two FLG loss-of-function
mutations (R501X and 2282del4) in 2006 (Smith et al., 2006),
these two mutations, along with the less prevalent S3247X
and R2447X, have been extensively studied and are present
in 7–10% of the white European population. Subsequently, a
total of 420 other rare or family-specific loss-of-function
mutations within FLG exon 3 have been discovered in
populations of white European ancestry. However, these
mutations are population specific and cannot be used for the
basis of genetic epidemiology studies in other populations.
The population specificity of FLG-null mutations indicates
that they have arisen after one population has split away from
another. Thus, populations arising from common ancestors
share common ancestral mutations, but populations that have
not experienced genetic admixture show different mutations.
The presence of rare and family-specific mutations indicates
that FLG-null mutations are still arising within the UK and
Irish populations that we have studied.
Asian populations have been shown to have their own
mutation spectra, following detailed study of the Japanese
population (Nomura et al., 2007, 2008, 2009; Enomoto et al.,
2008; Hamada et al., 2008; Nemoto-Hasebe et al., 2009b;
Osawa et al., 2010), and more recently the Han Chinese
(Zhang et al., 2011) and Singaporean Chinese populations
(Chen et al., 2008, 2011). In the white European population,
two prevalent FLG mutations account for over 80% of the
FLG-null alleles, whereas in the Singaporean Chinese
population there are eight different FLG-null mutations that
account for 80% of the spectrum of FLG mutations (Chen
et al., 2011).
The filaggrin story represents an unusual situation in
complex trait genetics because the causative variants are
either nonsense or frameshift mutations in a protein-encoding
exon, and therefore new causative variants can be identified
purely from their sequence. In contrast, the vast majority of
loci detected in other complex traits are anonymous regions
of DNA conferring disease susceptibility. Such loci are not
clearly associated with a specific gene, and the causative
variant(s) either remain unknown or require considerable
functional analysis to confirm and understand them. In the
case of filaggrin, the readily identifiable causative mutations
have revealed the complex genetic architecture of this locus,
where each ancestral population has it own unique spectrum
of mutations, some rare and some common, each of which
are found on a different haplotype of nearby SNPs. Thus,
individual SNPs can only reveal part of the signal coming
from the FLG locus, further masking its importance in
conferring eczema susceptibility.
A smaller number of FLG loss-of-function mutations have
so far been reported in other Asian populations, including
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Korean (Kang et al., 2009), Taiwanese (Hsu et al., 2009), and
Bangladeshi (Sinclair et al., 2009) ichthyosis vulgaris and
atopic eczema case collections plus one European patient
whose mother was from the Philippines (Greisenegger et al.,
2010). Until recently, FLG-null mutations had not been
detected within African populations, and an Ethiopian study,
including direct sequencing of FLG in 40 cases, has identified
only one loss-of-function mutation (Winge et al., 2011).
Furthermore, skin biopsies taken from seven of the Ethiopian
cases with palmar hyperlinearity did not show a reduction in
filaggrin expression as expected on immunohistochemistry
(Winge et al., 2011). These are small numbers from which to
draw any firm conclusions, but this study suggests that
ichthyosis vulgaris in the Ethiopian population may have a
different genetic mechanism from that seen in Europeans.
The prevalence of FLG-null mutations varies across
Europe, but R501X and 2282del4 are the two most common
mutations and they have consistently shown significant
association with atopic eczema across the continent
(Rodriguez et al., 2009), with the one exception of the Italian
population. R501X and 2282del4 are rare in Italian atopic
eczema cases (allele frequency o1% for each; Giardina
et al., 2008), and full sequencing of FLG exon 3, exon 2, and
the promoter region in a total of 220 Italian atopic dermatitis
patients identified only three additional mutations and no
association with atopic eczema (Cascella et al., 2011). The
pattern of FLG mutations in other Mediterranean populations
has not yet been examined, but the Italian data suggest that
different genetic factors may predispose to atopic eczema in
these populations and this warrants further investigation.
FILAGGRIN MUTATIONS MAY ACT AS GENETIC
MODIFIERS IN RARE GENODERMATOSES
It has been reported that the coexistence of FLG-null
mutations may be associated with a more severe phenotype
of X-linked ichthyosis (Liao et al., 2007) and pachyonychia
congenita (Gruber et al., 2009) within an affected family.
However, it is not possible to be certain whether FLG is truly
acting as a genetic modifier of disease in these single
pedigrees because each disease shows considerable inter-
individual variation and greater numbers of cases will be
needed to clarify this question.
WHAT IS THE ROLE OF FLG-RELATED BARRIER
DYSFUNCTION IN OTHER INFLAMMATORY DISEASES?
Other inflammatory barrier diseases, including Crohn’s
disease, ulcerative colitis, and sarcoidosis, share common
susceptibility loci with atopic eczema (Schreiber et al., 2005;
O’Regan et al., 2010a) but do not show association with
FLG-null mutations (Ruether et al., 2006; Van Limbergen
et al., 2009).
Autoantibody formation to citrullinated profilaggrin is a
highly sensitive and specific serological marker for rheuma-
toid arthritis (Sanmarti et al., 2009) and can predate the onset
of joint disease (Perez et al., 2007). Levels of anti-filaggrin
antibody may also correlate with arthritis activity (Choi et al.,
2005). However, filaggrin is not expressed in articular tissues
and these autoantibodies appear to be produced as a result of
crossreaction between deiminated peptide sequences, which
are present within fibrin chains in the synovium
(Mohrenschlager et al., 2006), and deiminated sequences
produced during the posttranslational processing of profilag-
grin (Perez et al., 2007). Anti-filaggrin antibodies are there-
fore not believed to be pathogenic (Van Steendam et al.,
2011). FLG-null mutations R501X, 2282del4, and 3702delG
have been studied in rheumatoid arthritis patients and
controls (Huffmeier et al., 2008), and FLG mutation carriers
showed no increased risk of developing rheumatoid arthritis.
However, in a separate study, FLG heterozygotes did show
significantly elevated levels of autoantibodies to citrullinated
peptides compared with controls (P¼0.018; Van Steendam
et al., 2011), and FLG-null mutations may therefore
contribute to the development of humoral autoimmunity in
early rheumatoid arthritis (Huffmeier et al., 2008) by an as yet
undefined mechanism.
Alopecia areata is a tissue-specific autoimmune disease,
and genetic factors make a significant contribution to its
etiology (Petukhova et al., 2010). Alopecia areata is known to
be associated with atopic disease and it has been shown that
comorbidity with atopic eczema, as well as the FLG-null
variants (R501X and 2282del4), predict a more severe form of
alopecia areata (Goh et al., 2006; Betz et al., 2007).
FLG DEMONSTRATES GENE–ENVIRONMENT
INTERACTIONS
Eczema is a complex trait, in which multiple genetic and
environmental factors contribute to pathogenesis, and the
interactions of several putative environmental risk factors for
atopic disease with FLG genotype have been investigated. It
has been hypothesized that FLG haploinsufficiency may
weaken the epidermal barrier and hence potentiate the
effects of environmental allergens (Bisgaard et al., 2008),
resulting in eczema. Birth cohort studies from Denmark and
the United Kingdom have shown that cat ownership early in
life increases the risk of atopic eczema as an additional effect
on top of the risk associated with FLG-null genotype, whereas
dog exposure has no effect (Bisgaard et al., 2008). A separate
cohort study from the Netherlands has replicated this finding,
showing an increased risk of atopic eczema in FLG-null
mutation carriers that is further enhanced by early-life
exposure to cats (Schuttelaar et al., 2009). However, these
data are difficult to interpret mechanistically because,
although other studies have shown an association of FLG-
null mutations with raised IgE to cat dander (Henderson et al.,
2008) and a significant correlation with atopic eczema
severity and specific IgE level for cat dander (Nemoto-Hasebe
et al., 2009a), there was no such association with sensitiza-
tion in the Danish or English cohorts.
Another key environmental influence early in life is the
presence or absence of other children, including siblings and
contacts in the day-care situation, as interactions with these
individuals may result in contact with pathogens and
allergens. Again, these complex epidemiological data are
difficult to interpret. A risk analysis of early childhood
eczema from a high-risk cohort of children born to mothers
with asthma showed no association with time spent in day
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care (Bisgaard et al., 2009), but interaction with FLG
genotype was not examined. Conversely, two large birth
cohort studies from Germany (Cramer et al., 2010) have
shown that children with FLG-null mutations have a
significantly higher risk of eczema if they have an older
sibling, and attendance at a day-care center lessened this risk
(Cramer et al., 2010). Environmental influences on eczema
pathogenesis are therefore not clearly defined, and these
findings demonstrate the importance of stratification for FLG
genotype in future epidemiological studies.
The development of irritant and allergic contact dermatitis
is largely dependent on environmental exposure to the irritant
or allergic substances, but FLG genotype is also a strong risk
factor. However, as discussed above, it is currently unclear
whether FLG haploinsufficiency is the risk per se, or whether
the risk is mediated via atopic eczema.
The coexistence of FLG mutations and early food
sensitization has been shown to improve the positive
predictive value for childhood asthma (Marenholz et al.,
2009). This observation was interpreted as a representation of
two distinct mechanisms interacting in the pathogenesis of
asthma (Marenholz et al., 2009). However, it is also possible
that the increased risk of asthma occurs as a result of
gene–environment interaction between FLG and food aller-
gen exposure. A deeper understanding of the mechanisms
within the atopic march will be required for the correct
interpretation of these interesting observations.
FILAGGRIN DEFICIENCY FORMS ONE PORTION OF A
COMMON PATHWAY IN ECZEMA PATHOPHYSIOLOGY
The filaggrin story demonstrates how the study of a
monogenic disorder can provide insight into complex trait
disease, and the striking significance of FLG-null mutations as
a genetic risk factor for atopic eczema has placed a new focus
on the role of barrier impairment in eczema pathogenesis.
There is an inherent barrier defect in atopic skin, which is
present even in the absence of eczema (Jakasa et al., 2006,
2007; Flohr et al., 2010), and it is clear that barrier
dysfunction can occur as a result of many different molecular
mechanisms—independently of filaggrin—but these are out-
with the scope of this current review. Focusing on filaggrin, it
is apparent that not all filaggrin deficiency is related to FLG-
null mutations, and downregulation of filaggrin may be
brought about by the interplay of other factors. The degree of
barrier impairment assessed by transepidermal water loss and
stratum corneum hydration shows some correlation with
FLG-null genotype (Jakasa et al., 2011), although active
inflammation further increases the degree of transepidermal
water loss (Nemoto-Hasebe et al., 2009a; Flohr et al., 2010).
Acute eczematous inflammation itself downregulates filag-
grin expression (Howell et al., 2007), and inflammatory
cytokines have been reported to downregulate filaggrin
expression in vitro, including IL-4 and IL-13 (Howell et al.,
2007), IL-22 (Gutowska-Owsiak et al., 2011), and IL-25 (Hvid
et al., 2011b). Inflammatory cytokines may also down-
regulate enzymes required for profilaggrin processing: IL-22
downregulates cathepsin D in vitro (Gutowska-Owsiak et al.,
2011) and T helper type 2–associated cytokines have been
shown to reduce caspase 14 mRNA levels in cultured
keratinocytes (Hvid et al., 2011a). Similarly, genetic variation
in enzymes known to have a role in profilaggrin processing,
including caspase 14 (Denecker et al., 2007; Hoste et al.,
2011), SASPase (Matsui et al., 2011), calpain I, and
bleomycin hydrolase (Kamata et al., 2011), may affect the
levels of functional filaggrin monomers. In this way,
inflammatory mediators and enzymatic processing within
the stratum corneum may each lead to filaggrin deficiency,
forming a common pathway in eczema pathophysiology.
LARGE COLLABORATIVE PROJECTS ARE REQUIRED
FOR THE INVESTIGATION OF GENETIC EFFECTS
ON A POPULATION LEVEL
One of the hidden stories within the filaggrin field is the fact
that many of the significant findings described above have
resulted from the collaborative work of national and
international groups of skin scientists and clinicians. The
work required ‘‘behind-the-scenes’’ to coordinate such
collaborations is not formally reported, but is clearly an
important part of the success of large studies. Similarly, the
organization required to collect high-quality samples and
clinical data from birth cohorts, case collections, and
population-matched control groups is a very significant
undertaking. Within the field of eczema research, there are
now several large cohorts and case collections that have been
used to further our understanding of the role of FLG genotype,
including the Irish case collection based in Dublin (Sandi-
lands et al., 2007; Weidinger et al., 2008a; O’Regan et al.,
2010a, b; Brown et al., 2011a); MAS (Marenholz et al., 2006),
KORA (Novak et al., 2008; Weidinger et al., 2008a), and
ETAC (Muller et al., 2009) in Germany; GENUFAC in
Northern Europe (Marenholz et al., 2006); PIAMA in the
Netherlands (Schuttelaar et al. 2009); COPSAC in Denmark
(Bisgaard et al., 2006, 2008; Bisgaard et al., 2009); ALSPAC
(Henderson et al., 2008; Weidinger et al., 2008a), NCCGP
(Brown et al., 2008a, 2009), and the EAT Study (Flohr et al.,
2010) in England; ADVN in the United States (Gao et al.,
2009); a Danish population sample (Thyssen et al., 2010a); a
Canadian peanut allergy cohort (Brown et al., 2011a); and
internationally, the ISAAC (Weidinger et al., 2008b). These
clinical resources will undoubtedly be useful in future
studies, and the established collaborative networks may be
used to facilitate clinical trials forthcoming from the
translational work as a result of new insight into genetic
factors in eczema pathogenesis.
WHAT MAY THE NEXT 25 YEARS HOLD FOR THE
FIELD OF ECZEMA GENETIC RESEARCH?
Key strategic goals for the field of eczema genetics in the next
25 years may be categorized into understanding pathome-
chanisms, methods for the prevention of atopic disease, and
therapy development (Figure 1).
There are several rather fundamental questions that remain
to be answered in relation to the filaggrin molecule: what are
the patterns of filaggrin expression throughout the body; what
are the mechanisms by which profilaggrin/filaggrin/amino
acids act in healthy tissues; and how exactly does filaggrin
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deficiency lead to eczema and other atopic diseases? We can
be reasonably optimistic that answers to these questions are
likely to emerge over the coming years, particularly in view
of the worldwide interest in filaggrin research. The field of
complex trait genetics is progressing rapidly, but one specific
challenge is the dissection of the multiple gene–gene
interactions that are likely to contribute to the heritability
that remains to be explained in atopic eczema. Some genetic
interactions with FLG have already been identified: FLG is
known to show an independent and multiplicative effect with
an eczema risk variant on 11q13.5 (O’Regan et al., 2010a)
and with polymorphisms in the genes encoding IL-10 and
IL-13 (Lesiak et al., 2011). However, many other examples of
genes interacting in the pathogenesis of atopic eczema are
likely to emerge, and these may well provide opportunities
for disease prevention and novel therapies. It is hoped and
anticipated that the application of next-generation sequen-
cing will speed up progress in the discovery of additional
eczema genes. An understanding of the importance of FLG
mutations in each population group will also facilitate the
identification of other important genetic factors. In parallel
with this, progress within the field of bioinformatics and
statistical genetics is vital in order to make sense of the vast
quantities of data produced by the latest high-throughput
sequencing.
A clearer understanding of gene–environment interaction
is needed in order to explain the significant rise in incidence
of atopic disease in the industrialized nations over the recent
decades. This will require careful epidemiological study of
human populations, but the use of mouse models of atopic
disease will also be useful in allowing experimental
manipulation of both genetic and environmental effects.
Gene–environment interactions are key to future preventative
strategies, with the ultimate aim of preventing atopic eczema
and halting the atopic march.
Another unanswered question is why filaggrin mutations
are so prevalent in various human populations? It has been
suggested that filaggrin deficiency may confer some hetero-
zygote advantage, and that ‘‘natural vaccination’’ against
microbial pathogens via the skin barrier may have driven
natural selection for these sequence variants during pandemics
in our ancient past (Irvine and McLean, 2006). Filaggrin-
deficient animal models should allow this question to be
addressed experimentally in the future (Fallon et al., 2009).
THERE IS POTENTIAL FOR THE APPLICATION OF
FILAGGRIN RESEARCH TO NOVEL THERAPEUTIC
APPROACHES AND PERSONALIZED MEDICINE
The understanding that has been gained from filaggrin
research offers real potential for future improvements in the
therapies available for atopic disease. It is clear that the
clinical phenotype of ichthyosis vulgaris–related eczema has
a poor prognosis in terms of atopic eczema, as well as
associated atopic asthma, allergic rhinitis, and food allergy.
We may therefore subclassify atopic eczema cases according
to FLG genotype for the purposes of pharmacogenetic studies.
Feasibility studies are currently underway in the United
Kingdom and United States to investigate the therapeutic
potential of barrier enhancement using emollients (BEEP,
2011), and experimental evidence is emerging to show that
the FLG gene is amenable to upregulation. Clarification of the
relative importance of the different functions of profilaggrin/
filaggrin/amino acids (Figure 3) will allow the further
development of strategies to enhance or replace these
molecules within human skin.
It is noteworthy that eczema, in contrast to psoriasis,
currently lacks any widely effective biological treatment, and
a clearer understanding of the key functional mechanisms in
atopy will be required to identify appropriate biological
targets. In the meantime, there is an opportunity to focus on
barrier improvement with bespoke emollients such as
ceramide-lipid (Elias, 2011) or filaggrin replacement. These
barrier improvement therapies have a lower likelihood of
undesirable systemic immune effects. Other potential ther-
apeutic strategies include the use of a peroxisome prolifer-
ator–activated receptor-a ligand along with topical
corticosteroid therapy, as peroxisome proliferator–activated
receptor-a ligand has been shown in a mouse model to have
anti-inflammatory synergy while reducing the barrier impair-
ment that results from topical steroids used in isolation
(Hatano et al., 2011). Tumor necrosis factor-a antagonists
improve the skin barrier in psoriasis (Kim et al., 2011), and
therefore may also be beneficial in eczema.
CONCLUDING REMARKS
In conclusion, the discovery of loss-of-function mutations
within the FLG gene represents the single most significant
breakthrough in understanding the molecular genetic me-
chanisms of a wide range of atopic and allergic disorders.
Future research into the remarkable filaggrin molecule holds
great potential to improve the care of atopic eczema patients
and ultimately to prevent the development of atopic disease.
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